tabula rasa healthcare tabula rasa healthcare  a family of companies  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases medication risk managementwe provide technology and services to atrisk healthcare organizations to optimize medication regimens  reducing hospitalizations lowering costs and reducing risk learn more educational toolsmarrying innovation and advanced technology to facilitate the cognitive practice of pharmacy niarx is novel educational software that provides complete realworld consultation experiences for pharmacy students learn more medicare risk adjustmentwe provide expert medicare risk adjustment services including coding and data analysis and submission for pace and similar organizations nationwide ensuring proper reimbursement and optimal utilization learn more pharmacy cost managementwe take a prospective approach to risk adjustment beyond retrospective reviews and claims data analysis we identify opportunities for efficiency and performance improvement in coding patterns data integrity and diagnosis volumes and trendslearn more leveraging technology to improve healthcare mrm technologiestrhc’s products and services are built around our medication risk mitigation matrix™ the mrm matrix™ enables optimization of a patient’s medication regimen by combining clinical and pharmacology data populationbased algorithms and extensive patientspecific data to deliver ‘precision medicine’ learn more  medication risk managementwe are trusted by organizations nationwide to deliver medication risk mitigation and distribution services that improve participant outcomes introduce lasting workflow efficiencies and increase medication safety learn more  medicare risk adjustmentwe provide expert medicare risk adjustment services including coding and data analysis for pace and similar organizations nationwide ensuring proper reimbursement and optimal utilization learn more  pharmacy cost managementwe are trusted to provide clients with timely insightful actionable reports at their fingertips services include price validation dispensing parameters bi tools utilization review and more learn more  recent newsuniversity of maryland names trhc ceo a pharmapreneur in celebration of the school of pharmacy’s th anniversarytrhc to provide care transition medication management for tandigm healthtrhc ceo knowlton named a fellow of the college of physicians of philadelphia tabula rasa healthcare tabula rasa healthcare  a family of companies  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases medication risk managementwe provide technology and services to atrisk healthcare organizations to optimize medication regimens  reducing hospitalizations lowering costs and reducing risk learn more educational toolsmarrying innovation and advanced technology to facilitate the cognitive practice of pharmacy niarx is novel educational software that provides complete realworld consultation experiences for pharmacy students learn more medicare risk adjustmentwe provide expert medicare risk adjustment services including coding and data analysis and submission for pace and similar organizations nationwide ensuring proper reimbursement and optimal utilization learn more pharmacy cost managementwe take a prospective approach to risk adjustment beyond retrospective reviews and claims data analysis we identify opportunities for efficiency and performance improvement in coding patterns data integrity and diagnosis volumes and trendslearn more leveraging technology to improve healthcare mrm technologiestrhc’s products and services are built around our medication risk mitigation matrix™ the mrm matrix™ enables optimization of a patient’s medication regimen by combining clinical and pharmacology data populationbased algorithms and extensive patientspecific data to deliver ‘precision medicine’ learn more  medication risk managementwe are trusted by organizations nationwide to deliver medication risk mitigation and distribution services that improve participant outcomes introduce lasting workflow efficiencies and increase medication safety learn more  medicare risk adjustmentwe provide expert medicare risk adjustment services including coding and data analysis for pace and similar organizations nationwide ensuring proper reimbursement and optimal utilization learn more  pharmacy cost managementwe are trusted to provide clients with timely insightful actionable reports at their fingertips services include price validation dispensing parameters bi tools utilization review and more learn more  recent newsuniversity of maryland names trhc ceo a pharmapreneur in celebration of the school of pharmacy’s th anniversarytrhc to provide care transition medication management for tandigm healthtrhc ceo knowlton named a fellow of the college of physicians of philadelphia healthcare and biotech stocks  seeking alphasign in  join nowgo»healthcare and biotech stocksathersyss cardiovascular health program is ambitious and wellcalculatedathx• today  pm • jesse donovan• commentskeep your eyes on bioverativ in bivv• today  pm • gaurao bhade• commentsgilead vosevi eu approval just one of several catalysts on the waygild• today  pm • jonathan faison• commentsamgen income on saleamgn• today  pm • samuel smith• commentscelgene guides up  and down how it plans to win the scelg• today  pm • doctorx• commentsdelcath massive dilution aheaddcth• today  pm • research  investment• commentsparatek beware of the expertsprtk• today  pm • early retiree• commentsare biotechs too risky for diy investorsibb xbi• today  pm • nicholas ward• commentsan upcoming discussion with a cardiologist on amarins vascepa and its potential in treating hypertriglyceridemiaamrn• today  pm • slingshot insights• commentsmy final thoughts on dynavax before todays advisory committee panel decision is announceddvax• today  pm • bret jensen• commentsacorda slump offers investment opportunityacor• today  am • emerging equities• commentxoma another ligand in the makingxoma• today  am • biotech phoenix• commentgilead sciences q not enough to move the stockgild• today  am • david butler• commentshillrom holdings inc  q  results  earnings call slideshrc• today  am • sa transcriptsan indepth analysis of calithera biosciences part cala• today  am • david hoffmannarbutus seeks to eradicate hep babus• today  am • strong bio• commentsgilead shut up about the cash and let management do their jobgild• today  am • orange peel investments• comments chart speaks volumes about gilead sciences futuregild• today  am • james brumley• comments things in biotech you should learn today july  antb btx incy• today  am • zach hartman phd• commentsglaxosmithkline doing an astrazeneca and a reckitt benckisereditors pick • gsk• today  am • dividend drive• commentsarena pharmaceuticals intriguing data and nearterm catalysts yet concerns remainarna• today  am • jonathan faison• commentscelgene expect the story to continuecelg• yesterday  pm • jonathan weber• commentsacorda investors are holding their breathacor• yesterday  pm • strong bio• commentsinteger holdings corporation  q  results  earnings call slidesitgr• yesterday  pm • sa transcriptsdynavax looking ahead to a long and tiring journeydvax• yesterday  pm • long term bio• commentscontrafect why hasnt anyone else done this alreadycfrx• yesterday  pm • altum research• commentsastrazeneca muddies the water as mystic failsazn• yesterday  pm • ep vantage• commentsglaxo runs into double trouble in hivgsk• yesterday  pm • ep vantage• commentamedisys inc  q  results  earnings call slidesamed• yesterday  pm • sa transcriptsgilead the greyhound leaves the doghousegild• yesterday  pm • doctorx• commentskeryx biopharmaceuticals inc  q  results  earnings call slideskerx• yesterday  pm • sa transcriptsgilead the doubters were wronggild• yesterday  pm • jonathan weber• commentsthe best balance sheets portfolio labcorplh• yesterday  pm • value prof• commentsnektar therapeutics further upside aheadnktr• yesterday  pm • jonathan faisontetraphase pharmaceuticals ignite data igniting share pricettph• yesterday  pm • jonathan faison• commentsultragenyx an interesting company in the rare disease spacerare• yesterday  am • biopharmaceutical wolfjohnson  johnson takes down medtronic and abbviejnj• yesterday  am • dj habig• commentsastrazeneca pipeline woesazn• yesterday  am • long term bio• commentsinvestors get a chance to load up on amgenamgn• yesterday  am • jonathan weber• commentsmystic falls at the first hurdleazn• yesterday  am • ep vantage• commentbiohaven pivots to take a shot at migrainebhvn• yesterday  am • strong bio• commentscelgene corporation  q  results  earnings call slidescelg• yesterday  am • sa transcriptsalexion pharmaceuticals inc  q  results  earnings call slidesalxn• yesterday  am • sa transcriptsboston scientific corporation  q  results  earnings call slidesbsx• yesterday  am • sa transcriptsamgen reports q short and longterm considerationsamgn• yesterday  am • doctorx• comments things in biotech you should learn today july  bmy mrk therf• yesterday  am • zach hartman phd• commentsopko contrarian play on positive updateopk• yesterday  am • avisol capital partners• commentswas the all clear just sounded on gileadgild• yesterday  am • bret jensen• commentswatch out for some solid action from vertex pharmaceuticals in vrtx• yesterday  am • gaurao bhade• commentsabiomed inc  q  results  earnings call slidesabmd• yesterday  am • sa transcriptsgilead sciences  there is still much to like about this company and its pricegild• yesterday  am • the value investor• commentsroche holding ltd adr  q  results  earnings call slidesrhhby• yesterday  am • sa transcriptssucampo a shift toward rare diseasesscmp• yesterday  am • oneil trader• commentinvitae set for growth  bret jensens idea of the montheditors pick • nvta• yesterday  am • bret jensen• commentsnow is a good time to buy johnson  johnsonjnj• yesterday  am • peter f way cfa• commentsvertex pharmaceuticals incorporated  q  results  earnings call slidesvrtx• wed jul   pm • sa transcripts• commentsgilead sciences inc  q  results  earnings call slidesgild• wed jul   pm • sa transcripts• commentsteva walking deadteva• wed jul   pm • mehdi zare• commentspfizers worrying trendpfe• wed jul   pm • searching for value• commentskindred bio pounces on feline weight managementkin• wed jul   pm • strong bio• commentsbiogen q  results few steps in the right directionbiib• wed jul   pm • healthbloggerbiogen positions itself for the futurebiib• wed jul   pm • jonathan weber• commentsglaxo gets out the axegsk• wed jul   pm • ep vantage• commentsolumiant clot signal echoes xeljanz experiencelly• wed jul   pm • ep vantagepetmed express  looks too high but ive been wrong beforeeditors pick • pets• wed jul   pm • vince martin• commentspaciras exparel expansion pain continuespcrx• wed jul   pm • ep vantagepfizer doesnt want to be left in the dust of avastin biosimilarpfe• wed jul   pm • long term bio• commentsexact sciences crushes estimates againexas• wed jul   pm • kirk spano• commentsvanda pharmaceuticals an early stage bioscience considerationvnda• wed jul   pm • dr tran biosci• commentssell gilead regardless of q resultsgild• wed jul   pm • shock exchange• comments things in biotech you should learn today july  bmy cur mrk• wed jul   pm • zach hartman phd• comments cheers for biogen which may be good enough to allow alphabiib• wed jul   pm • doctorx• commentsbuy the dip in reata pharmaceuticalsreta• wed jul   pm • jonathan faisonpick up  ytm with community health systems february  bondscyh• wed jul   pm • randy durig• commentsbuying abbott near its peakabt• wed jul   pm • black coral research• commentsnext page ipo preview tabula rasa healthcare inc  tabula rasa healthcare nasdaqtrhc  seeking alphasign in  join nowgo»ipo preview tabula rasa healthcare incsep  about tabula rasa trhc don dion longshort equity special situations momentum eventdrivenmarketplaceipo insightssummarynew jerseybased trhc provides technologyenabled products and services for medication management and risk adjustmentthe company is set to price its nasdaq ipo this wednesday evening sept  lead underwriters are ubs investment bank and wells fargo securitiestrhc plans to offer  million shares at an expected price range of  to  we hear the deal is in high demand and may price at the high endwe are keen on the companys valuation reported growth and market opportunity and suggest investors consider an allocationtabula rasa healthcare nasdaqtrhc expects to raise  million in its upcoming ipo  million if the underwriters exercise their option to purchase additional shares based in moorestown new jersey tabula rasa healthcare is a provider of technologyenabled products and services for medication management and risk adjustment we previewed this deal on our ipo insights platform tabula rasa healthcare will offer  million shares at an expected price range of  to  if the underwriters price the ipo at the midpoint of that range trhc will have a market capitalization of  million trhc filed for the ipo on january   lead underwriters ubs investment bank and wells fargo securities underwriters piper jaffray  co robert w baird  co and stifel nicolaus  co while some risks are present we like the company and the deal and suggest investors to buy this ipo business summary provider of products and services for medication management and risk adjustment tabula rasa healthcare inc provides patientspecific datadriven technology and solutions these enable healthcare organizations to optimize medication regimens tabulas solutions aim to enhance patient outcomes reduce hospitalizations and lower healthcare costs the companys cloudbased software applications include eirenerx which is used by atrisk healthcare organizations to access its patients medicationrelated information medwise advisor that allows for components of eirenerx to be used independently and by a broader healthcare audience and niarx an educational software platform used in the pharmacy educational community the company also serves prescribers and pharmacists use of proceeds and highlights from managements analysis the companys product revenue is generated through medication risk management contracts with healthcare organizations tabulas mrm matrix technology enables pharmacists to optimize tailored medication programs in  tabula began offering software solutions as standalone softwareasaservice currently all of the companys medication risk management clients have opted for bundled services no revenue has been derived from standalone offerings according to management quarterly revenue has grown consistently from  million for the first quarter of  to  million in the second quarter of  source sec filings for the six months ended june   and  product sales represented  and  respectively of total revenue and service revenue represented  and  respectively of total revenue impressive revenue retention and client retention rates were  and  respectively for  and  and  respectively for  tabula rasa healthcare intends to use the net proceeds of this ipo to pay down approximately  million in outstanding loans pay acquisition costs for certain assets and intellectual property and for general corporate purposes potential competition siemens pharmacy rxconnect pharmnet and others the pharmaceutical industry does offer competition in information systems peers include meditech pharmacy solutions horizon meds manager nasdaqhznp pharmnet willow from epiccare cpsi hms pharmacy siemens pharmacy rxconnect sunrise pharmacy and mediware yet tabula notes in its sec filings that it believes it is unique in its comprehensive medication risk management system using sales for the last twelve months ended june   tabula has a very reasonable ps multiple of  while competitor hznp has a slightly ps multiple of  industry average  source morningstar public research executive management highlights dr calvin knowlton bscpharm mdiv phd founded tabula rasa and serves as chairman and ceo he also founded carekinesis inc and enclara pharmacia inc he served as professor and department chair for the university of sciences in philadelphia in the s dr knowlton received his ba from rider college bachelor of science degree in pharmacy from temple university masters in divinity from princeton university and phd in pharmacoeconomics from the university of maryland cfo brian adams has served in his position since june  his previous experience comes from positions at carekinesis kpmg llp and excellerx inc mr adams earned his bachelor of science in business administration from the university of richmond conclusion consider an ipo allocation trhc shows strong revenue growth plans to use net proceeds from its ipo to pay down debt and is priced competitively in addition the space for patient risk management solutions is large and growing at its current valuation we are positive on this ipo and anticipate purchasing shares this week adjusted ebitda was  million and  million for year  and last six months ended june   respectively at present we hear the deal demand is strong and pricing could be at the upper end of the proposed range or higher disclosure iwe have no positions in any stocks mentioned but may initiate a long position in trhc over the next  hours i wrote this article myself and it expresses my own opinions i am not receiving compensation for it other than from seeking alpha i have no business relationship with any company whose stock is mentioned in this articleabout this articleexpandauthor payment   page view authors of pro articles receive a minimum guaranteed payment of tagged investing ideas ipo analysis healthcare specialized health serviceswant to share your opinion on this article add a commentdisagree with this article submit your ownto report a factual error in this article click herefollow don dion and get email alerts stock ideas  seeking alphasign in  join nowgo»stock ideasamazons stock is likely to pull back furtheramzn• today  pm • david zanoni• commentsgaming and ott the promising future of sonysne• today  pm • ian dyer• commentsapplied materials growth at a discountamat• today  pm • john diceccotesla could sell off on any bad news from these  eventstsla• today  pm • alex cho• commentsathersyss cardiovascular health program is ambitious and wellcalculatedathx• today  pm • jesse donovan• commentskeep your eyes on bioverativ in bivv• today  pm • gaurao bhade• commentsgilead vosevi eu approval just one of several catalysts on the waygild• today  pm • jonathan faison• commentsdryships it aint over yetdrys• today  pm • bill maurer• commentssnap big lockup expiration happens next weeksnap• today  pm • alex cho• commentsoracle is further growth possibleorcl• today  pm • egor kachalovamd vs intel winner of q earningsamd intc• today  pm • alex cho• commentshummingbird resources is getting ready to flyhumrf• today  pm • kevin vlerick• commentnew golds shares should experience significant nearterm gainsngd• today  pm • peter arendas• commentscelgene guides up  and down how it plans to win the scelg• today  pm • doctorx• commentseastside distillings capital raise  is this a nanocap to watchesdi• today  pm • ryan surber• commentsstatoil clearly undervalued with oil at sto• today  pm • michael fitzsimmons• commentswhy the longterm prosperity of baidu is guaranteedbidu• today  pm • motek moyen• commentsredfin ipo offers investors growth in an industry ripe for disruptionrdfn• today  pm • michael w byrne• commentsintel  transformation is on trackintc• today  pm • the value investor• commentswhy you should forget q and think about amazon long termamzn• today  pm • michael a ball• commentsdelcath massive dilution aheaddcth• today  pm • research  investment• commentsparatek beware of the expertsprtk• today  pm • early retiree• commentscocacola the forever companyko• today  pm • mike berner• commentslowering apples price target ahead of earningsaapl• today  pm • alex cho• commentsmatson weakness before earnings  buying opportunity or steer clearmatx• today  pm • james sands• commentsredfin is scheduled for a promising ipordfn• today  pm • nicholas durante• commentslargest acquisition to date a plus for starbuckssbux• today  pm • alt perspective• commentssap the right choices lead to the right outcomeseditors pick • sap• today  pm • bert hochfeld• commentsmicrosoft and sony benefit from reported overheating of the nintendo switchmsft sne• today  pm • motek moyen• commentsprocter  gamble  operational improvements are priced inpg• today  pm • the value investor• commentsyy inc is undervaluedyy• today  pm • john bay cfa• commentsatts new debt  not what youd expectt• today  pm • jonathan weber• commentsreorganization of nortel inversora finally set to unlock value for shareholders additional upside from telecomcablevision mergerntl• today  pm • pinestreet• commentstill upside for lufthansadlakf• today  pm • frederic laudenklos• commentacorda slump offers investment opportunityacor• today  am • emerging equities• commentteck an extremely good investmentteck• today  am • kmp ideas• commentsamd the sky is falling the sky is fallingamd• today  am • austin craig• commentsxoma another ligand in the makingxoma• today  am • biotech phoenix• commentthe skies are clear for omabeditors pick • omab• today  am • ian bezek• commentsellie maes quarterly miss an inflection pointelli• today  am • shareholders unite• commentsbanco bradesco sa  underappreciated stock for aggressive growth and incomebbd• today  am • bobak forouzanomnova solutions is the bull case set to play outomn• today  am • vince martinhub group  was the recent stock price run up too fast or did yesterdays earnings miss justify the stock price beatdownhubg• today  am • james sandschegg can the run continuechgg• today  am • michael battat• commentsexxon mobil this is most interestingxom• today  am • quad  capital• commentsits a fresh start the transition story of blackberrybbry• today  am • roy wang• commentsamazons horrible quarteramzn• today  am • detroit bear• commentskatanga mining  a view on its balance sheet and latest newskatff• today  am • marcel lange• commentsamazoncom the clear case for regulatory actionamzn• today  am • paulo santos• commentsbank of america and jpmorgan comparing financial ratiosbac jpm• today  am • chris b murphy• commentsaimias senior secured note  yield with assets supporting  recoveryeditors pick • gapff• today  am • jason li• commentsfoxconns american dream wisconsin shells out  billion to hon hai precision industryeditors pick • hnhaf• today  am • ramon vredeling• commentsarbutus seeks to eradicate hep babus• today  am • strong bio• commentssei investments development investment set to pay offseic• today  am • michael boyd• commentspresident trumps chief strategist wants to defang facebook and googlefb goog googl• today  am • david pinsen• commentsgnc did goldman sachs really just reiterate its  price targetgnc• today  am • courage  conviction investing• commentsgilead shut up about the cash and let management do their jobgild• today  am • orange peel investments• comments chart speaks volumes about gilead sciences futuregild• today  am • james brumley• comments things in biotech you should learn today july  antb btx incy• today  am • zach hartman phd• comments reasons to buy freeportfcx• today  am • leo nelissen• commentsglaxosmithkline doing an astrazeneca and a reckitt benckisereditors pick • gsk• today  am • dividend drive• commentsnatural health trends corporation buy it for value buy it for growthnhtc• today  am • ty huggins• commentsfly high american airlinesaal• today  am • chris hulsey• commentsnetgears q good enough to support a higher multipleeditors pick • ntgr• today  am • vince martin• commentsselloffs are an opportunity  cramers mad money amzn nflx goog• today  am • sa editor mohit manghnani• commentsfreeportmcmoran has bottomed at   cramers lightning round hsbc jpm fcx• today  am • sa editor mohit manghnani• commentstock exchange reading into retail moveseditors pick • avgo lb rh• today  am • jeff miller• commentsarena pharmaceuticals intriguing data and nearterm catalysts yet concerns remainarna• today  am • jonathan faison• commentswhat makes darden restaurants attractive in the long termdri• today  am • rck financial services• commentslogitech irrational selloff has created a dip buying opportunitylogi• today  am • hudson river capital research• commentscelgene expect the story to continuecelg• yesterday  pm • jonathan weber• commentsacorda investors are holding their breathacor• yesterday  pm • strong bio• commentstaseko mines new prosperity remains a long shottgb• yesterday  pm • elephant analytics• commentscolgatepalmolive reliable cash generatorcl• yesterday  pm • john diceccoinphi accelerating in the highspeed laneiphi• yesterday  pm • atanas baldzhiyski• commentsnext page ipo analysis  seeking alphasign in  join nowgo»ipo analysisredfin ipo offers investors growth in an industry ripe for disruptionrdfn• today  pm • michael w byrne• commentsredfin is scheduled for a promising ipordfn• today  pm • nicholas durante• commentsredfin ignores the elephantsrdfn• yesterday  am • ipo candy• commentsthe next generation of mlp iposkrp hesm amgp• yesterday  am • alerianin the already saturated market of southern california can another chineseamerican bank succeedrbb• wed jul   pm • samantha hendrie• commentsredfin finalizes terms for  million ipordfn• wed jul   am • donovan jones• commentsredfin ipo tech company changing real estate industryrdfn• wed jul   am • don dion• commentssienna biopharmaceuticals expected to ipo on thursdaysnna• wed jul   am • don dion• commentscommercial bank rbb bancorp prepares for iporbb• tue jul   pm • don dion• commentsvenator materials readies  million ipo from huntsmanvntr• tue jul   pm • donovan jones• commentsbrokerage or tech firm redfins valuation requires the latterrdfn• tue jul   am • david trainer• commentsredfin ipo tech company real estate brokerage or something newrdfn• tue jul   am • fish and tips• commentsthemaven updates large insider share registrationmven• tue jul   am • donovan jones• commentsus ipo weekly recap investors remain discerning amid increased activitytrtx petq kala• sat jul   am • renaissance capital ipo researchbilliondollar unicorns draftkings faces hurdlesdraft• fri jul   pm • sramana mitranew chance to buy into shares of tintri at ipo quiet period expirationtntr• fri jul   pm • don dion• commentwag of approval for petiqpetq• fri jul   pm • don dion• commentsbyline banc investors could cash in at upcoming ipo quiet period expirationby• wed jul   am • don dionyogaworks flexes its muscles preipoyoga• wed jul   am • don dion• commentscalyxt inc regulatory hurdles keep us cautious on this otherwise exciting ipoclxt• wed jul   am • don dion• commentskala pharmaceuticals looks promising ahead of ipokala• tue jul   pm • don dion• commentsipo lockup expiration for laureate education could school investorslaur• tue jul   am • don dion• commentsus ipo weekly recap  health care companies price snap breakssnap akca codx• sat jul   pm • renaissance capital ipo researchus ipo week ahead diverse ipo week has yoga pet meds and geneedited cropsrdfn cmta vntr• sat jul   pm • renaissance capital ipo researchrev group driving downward ahead of ipo lockup expirationrevg• fri jul   am • don dion• commentis snapchat finished a look at its falling stocksnap• fri jul   am • richard ashton• comments questions to ask before you invest in that ipoipo• thu jul   pm • stansberry churchouse researchblue apron  cohort data suggests favorable unit economicseditors pick • aprn• thu jul   pm • kevin mak cfa• commentscalyxt sets proposed terms for  million ipoclxt• tue jul   pm • donovan jones• commentsaltice is wired to soar ahead of quiet period expirationatus• tue jul   am • don dion• commentsredfin ipo the modern way to a homerdfn• tue jul   am • don dion• commentsshotspotter the right ipo at the right timessti• mon jul   pm • jonathan faison• commentsblue apron future bleak at bestaprn• mon jul   pm • galileo russell• commentswill snap become just another broken ipoeditors pick • snap• mon jul   pm • bull  bear trading• commentssiennas ipo partner and product concernssnna• mon jul   am • richard ashton• commentsblue apron an unclear moat and a questionable path aheadaprn• sun jul   pm • jacob urban• commentsus ipo week ahead  health care companies scheduled for a slow weekakca yoga adv• sat jul   pm • renaissance capital ipo research• commentsus ipo weekly recap no ipos during the july th weekaprn cmta kala• sat jul   pm • renaissance capital ipo research• commentesquire financial holdings ipo the jury is still outesq• fri jul   am • alexander valtsev• commentshiftpixy the most promising reg a ipo yetpixy• thu jul   pm • abu bakr hussain• commentsbilliondollar unicorns looker counts on big data analyticslook• wed jul   pm • sramana mitra• commentsredfin ipo real estate redefinedrdfn• wed jul   pm • fish and tips• commentsblue apron down but far from outaprn• wed jul   am • richard ashton• commentstintri ipo the fundamental problemstntr• wed jul   am • richard ashton• commentswhat does blue aprons ipo tell us about the market climateaprn• wed jul   am • orange peel investments• commentspreferred stock ipo  from pennymac mortgage investment trustpmt• mon jul   pm • arbitrage trader• commentsathenex an undertheradar buying opportunityatnx• mon jul   am • don dion• commentsyogaworks stretches for an ipoyoga• mon jul   am • nicholas durante• commentsblue apron will only give investors the bluesaprn• sun jul   pm • michael carter• commentsus ipo weekly recap blue apron breaks in a busy week for iposatxi dova esq• sat jul   pm • renaissance capital ipo researchus ipo week ahead one biotech ipo scheduled for the short holiday weekakca frnt yoga• sat jul   am • renaissance capital ipo researchblue apron nothing special hereaprn• fri jun   pm • david luo• commentswhy sa contributors have gotten blue apron all wrongaprn• fri jun   pm • chenango capital llc• commentsdoor opens for bdc ipos after  year drought middle market to grow more crowdedcgbd• fri jun   am • kelly thompson• commentstintri walks like a duck talks like a ducktntr• fri jun   am • ipo candy• commentlogistics provider beats fintechs to ipo gatebesti• thu jun   pm • doug young• commentinvest in what you know but what about ipos thu jun   pm • td ameritradetintri  many challenges for this ipotntr• thu jun   pm • the value investor• commentsblue apron  a lot of questions following worrisome q trendsaprn• thu jun   pm • the value investor• commentsblue apron cuts ipo rangeaprn• thu jun   pm • nicholas durante• commentsblue apron is this weak ipo tasty nowaprn• thu jun   am • stone fox capital• commentsbest inc ipo questions must be answeredbesti• wed jun   am • richard ashton• commentsipos are buzzy but do they live up to the hypeamzn fb fit• wed jun   am • td ameritrade• commentsthe basics of ipos some things you should know wed jun   am • td ameritradetintri cloudy financials ahead of ipotntr• wed jun   am • don dion• commentsblue apron tasty food not so appetizing ipo especially for longterm gainsaprn• tue jun   pm • apac investment news• commentsdova pharmaceuticals a different business model could lead to successdova• tue jun   pm • don dion• commentskala pharmaceuticals files for  million ipokala• tue jun   pm • donovan jones• commentcalyxt files for  million ipo in cellectis carveoutclxt• tue jun   am • donovan jones• commentbiopharm aileron therapeutics ipo set for thursday were cautiousalrn• tue jun   am • don dion• commentsakcea a wholly owned subsidiary of ionis pharmaceutical set to ipoakca• tue jun   am • don dion• commentstrivago ipo sixmonth report cardtrvg• tue jun   am • ipo candy• commentsblue apron a pricey meal ahead of the ipoaprn• tue jun   am • don dion• commentsipo puts altice usas best program behind itatus• mon jun   pm • lipper alpha insightcommercial bank byline corp looks overvalued ahead of ipoby• mon jun   pm • don dion• commentsnext page insider trading activity tabula rasa healthcare inc nasdaqtrhc – insider sold  shares of stock  market exclusive sign in join home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps sign in welcomelog into your accountyour usernameyour password forgot your password sign up welcomeregister for an account your emailyour username a password will be emailed to you password recovery recover your passwordyour email search sign in  joinmy account orders sign inwelcome log into your accountyour usernameyour password forgot your password get helpcreate an account create an accountwelcome register for an accountyour emailyour username a password will be emailed to you password recoveryrecover your passwordyour email a password will be emailed to you market exclusive home about us privacy policy disclaimer advertise on market exclusive about marketexclusivecom contributors sitemap submit a scoop contact us become a contributor stock market news stocks analyst ratings insider trading sec filings earnings biotech stocks small caps home insider trading insider trading activity tabula rasa healthcare inc nasdaqtrhc – insider sold  insider trading insider trading activity tabula rasa healthcare inc nasdaqtrhc – insider sold  shares of stock byme staff july    share on facebook tweet on twitter insider trading activity for tabula rasa healthcare inc nasdaqtrhc orsula v knowlton  insider of tabula rasa healthcare inc nasdaqtrhc reportedly sold  shares of the company’s stock at an average price of  for a total transaction amount of  sec form insider trading history for tabula rasa healthcare inc nasdaqtrhc on  joann m durham major shareholder sold  with an average share price of  per share and the total transaction amounting to view sec filing on  glen r bressner director bought  with an average share price of  per share and the total transaction amounting to view sec filing on  orsula v knowlton insider sold  with an average share price of  per share and the total transaction amounting to view sec filing on  glen r bressner director bought  with an average share price of  per share and the total transaction amounting to view sec filing on  gordon tunstall director sold  with an average share price of  per share and the total transaction amounting to view sec filing on  orsula v knowlton insider sold  with an average share price of  per share and the total transaction amounting to view sec filing on  orsula v knowlton insider sold  with an average share price of  per share and the total transaction amounting to view sec filing analyst ratings for tabula rasa healthcare inc nasdaqtrhcthese are  buy ratings the current consensus rating for tabula rasa healthcare inc nasdaqtrhc is buy score  with a consensus target price of   a potential  upside analyst ratings history for tabula rasa healthcare inc nasdaqtrhc on  wells fargo  company initiated coverage of rating outperform on  robert w baird set price target of rating buy with a price target of  on  piper jaffray companies boost price target of rating overweight with a price target of  to  on  chardan capital initiated coverage of rating buy to buy with a price target of  on  stifel nicolaus reiterated rating buy with a price target of  recent trading activity for tabula rasa healthcare inc nasdaqtrhcshares of tabula rasa healthcare inc closed the previous trading session at  down   with  shares trading hands please enable javascript to view the comments powered by disqusan ad to help with our costs related articlesmore from author insider trading activity summer energy holdings inc nasdaqsume – cfo bought  shares of stock insider trading activity power integrations inc nasdaqpowi – director sold  shares of stock insider trading activity pnc financial services group inc the nysepnc – insider sold  shares of stock insider trading activity opko health inc nasdaqopk – ceo bought  shares of stock insider trading activity old line bancshares inc nasdaqolbk – director bought  shares of stock insider trading activity old line bancshares inc nasdaqolbk – director bought  shares of stock subscribe to our newsletter email  first namelast nameemail a word from the sponsor latest articles pingtan marine enterprise ltd nasdaqpme files an k results of operations and financial condition rayonier advanced materials inc nyseryam files an k financial statements and exhibits armstrong world industries inc nyseawi files an k submission of matters to a vote of security holders recent posts insider trading activity tabula rasa healthcare inc nasdaqtrhc – insider sold  shares of stock insider trading activity summer energy holdings inc nasdaqsume – cfo bought  shares of stock insider trading activity power integrations inc nasdaqpowi – director sold  shares of stock insider trading activity pnc financial services group inc the nysepnc – insider sold  shares of stock insider trading activity opko health inc nasdaqopk – ceo bought  shares of stock sponsored editor picks here’s what just happened with ironwood pharmaceuticals inc nasdaqirwd and aeterna july   here’s what just happened with sarepta therapeutics inc nasdaqsrpt july   biotech movers vertex pharmaceuticals incorporated nasdaqvrtx and inovio pharmaceuticals inc nasdaqino july   popular posts this small nasdaq hidden gem may have a b drug july   weekly biotech report covering – opko health inc nyseopk intercept april   facebook inc – nasdaqfb might be moving away from its april   popular categorysec filingslseanalyst ratingsstockstech newsbiotech stocksstock market newssmall capscanada about usmarket exclusive offers the latest financial news and analysis for selected us stocks and securities we are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions at market exclusive we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices market exclusive is not a registered investment brokerdealer the content on this site is for informational purposes only additionally the content on this site does not represent the views of market exclusive and is solely a representation of the authors who publish them before investing in any security you should do your own due diligence and consult with a registered broker or financial advisorcontact us email protectedfollow us sec filings stocks stock market news tech news biotech stocks featured small caps gold other news oil become a contributor about marketexclusivecom contributors advertise on market exclusive contact us  market exclusive  tabula rasa healthcare inc private company information  bloomberg july    pm et health care technology company overview of tabula rasa healthcare inc snapshot people company overview tabula rasa healthcare inc provides patientspecific datadriven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes reduce hospitalizations lower healthcare costs and manage risk its cloudbased software applications include eirenerx which is used by atrisk healthcare organizations to access its patients medicationrelated information medwise advisor that allows for components of eirenerx to be used independently and by a broader healthcare audience and niarx an educational software platform used in the pharmacy educational community the company offers its technologyenabled products and services for medicat tabula rasa healthcare inc provides patientspecific datadriven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes reduce hospitalizations lower healthcare costs and manage risk its cloudbased software applications include eirenerx which is used by atrisk healthcare organizations to access its patients medicationrelated information medwise advisor that allows for components of eirenerx to be used independently and by a broader healthcare audience and niarx an educational software platform used in the pharmacy educational community the company offers its technologyenabled products and services for medication risk management and risk adjustment it also serves prescribers pharmacists and healthcare organizations tabula rasa healthcare inc was founded in  and is headquartered in moorestown new jersey detailed description  strawbridge drivesuite moorestown nj united statesfounded in  employees phone  wwwtabularasahealthcarecom key executives for tabula rasa healthcare inc dr calvin h knowlton bsc pharm mdiv phd cofounder chairman of the board and chief executive officer age  total annual compensation k dr orsula v knowlton bscpharm pharmd mba cofounder president and director age  total annual compensation k mr brian w adams chief financial officer age  total annual compensation k compensation as of fiscal year  tabula rasa healthcare inc key developments tabula rasa healthcare inc signs first licensing deal may   tabula rasa healthcare inc has for the first time licensed the use of its medication risk mitigation technology to an outside organization the moorestown nj company has entered into an agreement that provides access for its medwise advisor technology to landmark a national medical group based in huntington beach calif that focuses exclusively on chronically ill patients financial terms of the deal were not disclosed the medwise advisor platform will be used by landmark clinicians to identify opportunities to improve the safety of their members medication profiles in addition tabula rasas pharmaciststaffed call centers also will provide asneeded clinical support to landmarks clinicians first phase of the program will be launched by landmark in two of its markets california and new york knowlton said existing medication management software only looks at onetoone drug interactions and dont take into account patients on multiple prescriptions and overthecounter medications tabula rasas technology is designed not only to protect the safety of patients on numerous medications its clinical support tools also help clinicians make choices to improve medication outcomes tabula rasa healthcare inc announces unaudited consolidated earnings results for the first quarter ended march   provides earnings guidance for the second quarter and full year of  may   tabula rasa healthcare inc announced unaudited consolidated earnings results for the first quarter ended march   for the quarter the company reported total revenue of  against  a year ago loss from operations was  against income from operations of  a year ago loss before income taxes was  against income before income taxes of  a year ago net loss was  against net income of  a year ago basic and diluted net loss attributable to common stockholders was  against diluted net income attributable to common stockholders of  a year ago basic and diluted net loss per share attributable to common stockholders was  against diluted net income per share attributable to common stockholders of  a year ago adjusted ebitda was  against  a year ago adjusted net income attributable to common stockholders was  or  per diluted share against  or  per diluted share a year ago net cash provided by operating activities was  against  a year ago purchases of property and equipment were  against  a year ago the increase in adjusted ebitda was primarily driven by growth in the business both in the pace market and payor and atrisk provider market for the second quarter of  revenue is expected to be in the range of  million to  million net loss is expected to be in the range of  million to  million net loss projections include incremental stockbased compensation expense of approximately  million related to restricted stock grants issued in connection with company’s initial public offering adjusted ebitda is expected to be in the range of  million to  million for the full year  revenue is expected to be in the range of  million to  million net income is expected to be in the range of negative  million to positive  million net income projections include incremental stockbased compensation expense of approximately  million related to restricted stock grants issued in connection with company’s initial public offering which will be fully expensed by may  there are no debt extinguishment charges anticipated in  adjusted ebitda is expected to be in the range of  million to  million tabula rasa healthcare inc annual general meeting jun   may   tabula rasa healthcare inc annual general meeting jun   at  us eastern standard time location  strawbridge drive suite  moorestown new jersey united states agenda to elect the three class i director nominees named in the proxy statement to serve on board of directors until our  annual meeting of stockholders and until their successors are duly elected and qualified to ratify the selection of kpmg llp as independent registered public accounting firm for the fiscal year ending december   and to conduct any other business properly brought before the annual meeting similar private companies by industry company name region mpirik llc united states  inc united states eq inc united states healthyworld inc united states over inc united states recent private companies transactions typedate target buyback may    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact tabula rasa healthcare inc please visit wwwtabularasahealthcarecom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close trhcnasdaq gm stock quote  tabula rasa healthcare inc  bloomberg markets error could not add to watchlist x  watchlist tabula rasa healthcare inc trhcus nasdaq gm usd   as of  pm edt  open  day range    volume  previous close  wk range    before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range    ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry health care equipment  services  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later  tabula rasa healthcare ceo is keynote presenter at the american society for automation in pharmacy’s  midyear conference  tabula rasa healthcare to announce second quarter  operating results and host conference call on monday august    tabula rasa healthcare to provide care transition medication management for tandigm health  tabula rasa healthcare to participate in the  ubs global healthcare conference  tabula rasa healthcare and landmark to improve patient outcomes in california and new york    tabula rasa healthcare announces first quarter  operating results  tabula rasa healthcare to announce first quarter  operating results and host conference call on monday may    tabula rasa healthcare to participate in the th annual needham healthcare conference  tabula rasa healthcare announces fourth quarter and full year  operating results  tabula rasa healthcare to present at the american society for clinical pharmacology and therapeutics annual meeting there are currently no press releases for this ticker please check back later profile tabula rasa healthcare inc designs and develops cloudbased healthcare software solutions the company offers datadriven technology and solutions that enable healthcare organizations to optimize medication regimens tabula rasa healthcare operates in the united states address  strawbridge drivesuite moorestown nj united states phone  website wwwtabularasahealthcarecom executives board members calvin h knowlton chairmanceocofounder orsula v knowlton presidentcofounder brian w adams chief financial officer philip w heath chief administrative officer joseph j filippoli chief information officer show more tabula rasa healthcare our software  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases our software medwise advisor software provides the medication decision support components of eirenerx primarily our mrm matrix to support clients seeking to manage their medication risk and improve medication outcomes and patient relationships by enhancing their existing systems medwise advisor can be integrated with a variety of eprescribing modules ehrs pharmacy management systems clinical systems case management platforms and other clinical databases our expert pharmacists are available to perform clinical analysis of the results and when necessary offer guidance based upon their review of the mrm matrix and patient medical history medwise advisor is broadly applicable to all organizations that employ clinicians who prescribe medications and those with pharmacists or other clinicians that provide support to prescribers mymedwise advisor is the consumerfacing version of our medication safety technology mymedwise advisor empowers patients and translates the science of medications into easytounderstand guidelines and alerts eirenerx is our cloudbased medication decisionsupport and eprescribing platform this technology enables one shared medication information system among physicians nurses other authorized caregivers and pharmacists eirenerx includes a computerized order entry module with which healthcare organizations access patient medicationrelated information and use our personalized proprietary mrm matrix with eirenerx prescribers and our pharmacists collaborate on patient medication management in real time our pharmacists are available  to perform clinical analysis of the mrm results and assist prescribers in personalizing patient medication regimens eirenerx provides several communication workflows through which our pharmacists can answer questions and make clinical recommendations eirenerx™ version  has achieved onc hit  edition modular ambulatory ehr certification this certification designates that the software is capable of supporting eligible providers with meeting the stage  and stage  meaningful use measures required to qualify for funding under the american recovery and reinvestment act arra eirenerx™ version  meets certification criteria that include computerized provider order entry cpoe eprescribing medication list medication allergy list drugdrug and drugallergy interaction checks drug formulary checks automated numerator capture authentication access control and authorization safetyenhanced design quality management system eirenerx is integrated with our adherencepackaging pharmacies which deliver medications to patients nationwide eirenerx module certificates and disclosures can be found here niarx is a cloudbased software platform designed to facilitate the cognitive practice of pharmacy through casebased learning utilizing the mrm matrix niarx is in use by six schools of pharmacy with more than  registered academic users it is intended to build literacy and brand awareness of our suite of technology solutions with thoughtleaders and students in the pharmacy educational community and drive adoption in the professional pharmacy community we’re hiring systems administrator risk adjustment coder nurse risk adjustment and coding specialist contact information  infotabularasahealthcarecom  strawbridge drivemoorestown nj  tabula rasa healthcare leadership  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases leadership  guiding our path  the leadership teams of tabula rasa healthcare companies have been working together for many years – in some cases as long as  years – in various companies calvin h knowlton bscpharm mdiv phdceo chairman and founderdr knowlton has won numerous awards for his leadership in pharmacy business and philanthropy in his career of over  years including the  and the  ernest and young entrepreneur of the year award greater philadelphia region and the  walter m aikman entrepreneur of the year award he was selected as the most… read more  orsula v knowlton pharmd mbapresidentdr orsula knowlton coauthored the first published consensus guidelines on the standards for anticoagulation management centers in conjunction with the anticoagulation forum she has authored and coauthored book chapters and articles focused on pharmaceutical care and medication therapy management read more  brian w adamschief financial officerjoining carekinesis in late  mr adams leads the finance accounting treasury and risk management functions mr adams has broad experience in financial management strategic planning business performance optimization and financial integration for mergers and acquisitions read more  robert l alesiani pharmd cgpchief pharmacotherapy officerdr robert l alesiani leads the medication care plan support center for carekinesis he is one of the first clinical pharmacists in the us with training and expertise to provide pharmacogenomic testing coordination and translation for people on highrisk medications read more  joseph j filippoli mbachief information officermr filippoli is a year veteran of the information technology industry with a particular focus on leading healthcare technology operations application development informatics and technology innovation mr filippoli’s expertise and experience allow him to bridge many facets of information management and healthcare delivery read more  michael greenhalgh rphchief operating officermr greenhalgh is the chief operating officer of carekinesis inc and the chief pharmacy officer of tabula rasa healthcare as a founding member of carekinesis mr greenhalgh was the chief architect and designer of all pharmacy operations read more  phillip w heath mschief administrative officerphillip w heath has been the chief administrative officer since february  in this position he oversees the operations of the family of companies under tabula rasa healthcare read more  brian j litten esqchief strategy officer  general counselbrian litten is an attorney a healthcare policy strategist and a healthcare management executive he has served in leadership roles with two large health plans and with one large health system with a concentration in healthcare strategy and company positioning advising management on growth potential and market opportunities read more  richard o schamp md cmd chcqmchief executive officer capstone performance systemsdr richard schamp md has over  years’ experience in geriatric care he provides medicare risk adjustment support to pace organizations across the united states dr schamp has worked with over half the pace organizations in the us and is an industry expert read more  jacques turgeon bpharm phdchief scientific officerdr turgeon has been the chief scientific officer since september  dr turgeon is recognized internationally for his work on cyps and mechanisms of drugdrug interactions read more  tabula rasa healthcare our brands  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases our brands bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one trhc key statistics  tabula rasa healthcare inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close tabula rasa healthcare inc nasdaq trhc go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus tabula rasa healthcare inc after hours  quotes are delayed by  min jul    pm trhc quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description tabula rasa healthcare inc engages in the provision of personalized medication therapy management and pharmacy services to reduce medication risk it provides patientspecific datadriven technology and solutions that enable healthcare organizations to optimize medication regimens to improve pati tabula rasa healthcare inc engages in the provision of personalized medication therapy management and pharmacy services to reduce medication risk it provides patientspecific datadriven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes reduce hospitalizations lower healthcare costs and manage risk the company was founded by calvin h knowlton and orsula v knowlton in april  and is headquartered in moorestown nj valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  price to cash flow ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr calvin h knowlton   chairman  chief executive officer dr orsula v knowlton   president director  chief marketing officer mr michael greenhalgh   chief operating officer mr brian w adams   chief financial officer dr jacques turgeon   chief scientific officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  orsula v knowlton president director    disposition at  per share   orsula v knowlton president director    disposition at  per share   a gordon tunstall director    award at  per share   dennis helling director    award at  per share   orsula v knowlton president director    disposition at  per share   calvin h knowlton chief executive officer director    disposition at  per share   a gordon tunstall director    disposition at  per share   orsula v knowlton president director    disposition at  per share   calvin h knowlton chief executive officer director    disposition at  per share   a gordon tunstall director    derivativenonderivative trans at  per share   a gordon tunstall director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   orsula v knowlton president director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   calvin h knowlton chief executive officer director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   originate ventures llc director    derivativenonderivative trans at  per share   radius ventures llc    derivativenonderivative trans at  per share   radius ventures llc    derivativenonderivative trans at  per share   radius ventures llc    derivativenonderivative trans at  per share   rittenhouse ventures llc director    derivativenonderivative trans at  per share   rittenhouse ventures llc director    derivativenonderivative trans at  per share   rittenhouse ventures llc director    derivativenonderivative trans at  per share   rittenhouse ventures llc director    derivativenonderivative trans at  per share   john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      john durham      brian w adams chief financial officer    award at  per share   eric arnson    acquisition at  per share   radius ventures llc      radius ventures llc      radius ventures llc      john durham    disposition at  per share   john durham    disposition at  per share   john durham      brian w adams chief financial officer    derivativenonderivative trans at  per share  newslatestcompanyustrhc marketwatch news on trhc tabula rasa healthcare started at overweight with  stock price target at piper jaffray  am oct    tomi kilgore tabula rasa healthcare started at buy with  stock price target at stifel nicolaus  am oct    tomi kilgore tabula rasa healthcare started at outperform with  stock price target at rw baird  am oct    tomi kilgore newsnonmarketwatchcompanyustrhc other news on trhc premarket analyst action  healthcare  am july    seeking alpha breakout watch thinly traded health care ipo enters buy zone  am july    investors business daily american assets trust inc aat and tangoe inc tngo lead  notable investor filings  am june    investorplacecom q tabula rasa healthcare inc  am may    edgar online  edg  q k tabula rasa healthcare trhc presents at th annual needham healthcare conference  slideshow  pm april    seeking alpha sell tabula rasa healthcare  am march    seeking alpha k tabula rasa healthcare inc  am march    edgar online  edg  q k can tabula rasa trhc run higher on strong earnings estimate revisions  pm dec    zackscom tabula rasa healthcares trhc ceo calvin knowlton on q  results  earnings call transcript  pm nov    seeking alpha q tabula rasa healthcare inc  am nov    edgar online  edg  q k healthcare ratings roundup  new coverage  pm oct    seeking alpha ipo quiet period expiration for tabula rasa healthcare presents a buying opportunity  pm oct    seeking alpha tabula rasa healthcare insider trades  pm oct    gurufocuscom  ipo update winners losers and highlights for ipos on deck  am sept    seeking alpha ipo preview tabula rasa healthcare inc  pm sept    seeking alpha tabula rasa healthcare ipo is about risk management  am sept    seeking alpha tabula rasa healthcare on deck for ipo  pm sept    seeking alpha at a glance tabula rasa healthcare inc  strawbridge drive moorestown new jersey  phone   industry software sector technology fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for trhc newspressreleasecompanyustrhc press releases on trhc tabula rasa healthcare ceo is keynote presenter at the american society for automation in pharmacys  midyear conference technologys role in pharmacy  pm july    globenewswire tabula rasa healthcare to announce second quarter  operating results and host conference call on monday august    am july    globenewswire tabula rasa healthcare to provide care transition medication management for tandigm health  am june    globenewswire tabula rasa healthcare to participate in the  ubs global healthcare conference  pm may    globenewswire tabula rasa healthcare and landmark to improve patient outcomes in california and new york  pm may    globenewswire tabula rasa healthcare announces first quarter  operating results  pm may    globenewswire investor network tabula rasa healthcare inc to host earnings call  am may    accesswire tabula rasa healthcare to announce first quarter  operating results and host conference call on monday may    am april    globenewswire tabula rasa healthcare to participate in the th annual needham healthcare conference  am march    globenewswire tabula rasa healthcare to present at the american society for clinical pharmacology and therapeutics annual meeting  am march    globenewswire former kaiser permanente executive elected to trhc board of directors  am march    globenewswire tabula rasa healthcare launches its first care transitions intervention program for a large healthcare plan  pm march    globenewswire tabula rasa healthcare moves its san franciscobased operations to a larger technologically advanced facility  am feb    globenewswire tabula rasa healthcare launches part d enhanced medication therapy management program to improve medication use  am feb    globenewswire tabula rasa healthcare to announce fourth quarter and full year  operating results and host conference call on monday march    pm feb    globenewswire groundhog day investment forecast sun or clouds for stocks  am jan    businesswire  bzx  outlook and insights investment trends and themes to be highlighted at the emerald groundhog day investment forum  am jan    businesswire  bzx tabula rasa healthcare signs three year agreement to provide medication care management for multistate pace sponsor  am jan    globenewswire tabula rasa healthcare and mediture announce launch of custom integration to enhance workflow and help optimize pace outcomes  pm dec    globenewswire tabula rasa healthcare to participate in the th annual piper jaffray healthcare conference  pm nov    globenewswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  tabula rasa healthcare awards  recognition  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases awards  recognition tabula rasa healthcare and its leadership continue to be honored by and recognized for outstanding achievement in pharmacy business professional affiliations and community outreach technology ceo of the year dr calvin h knowlton enterprise awards philadelphia alliance for capital  technologies  executive management award joseph j filippoli mba smartceo   academy of medicine france inductee dr jacques turgeon one of the only pharmacists and the first pharmacist from canada  recipient nj economic development authority jobgrowth funding   health innovator company of the year enterprise awards philadelphia alliance for capital  technologies  woman business leader dr orsula v knowlton women’s business forum burlington county regional chamber of commerce   community partners of the year drs calvin h and orsula v knowlton notprofit development center of southern new jersey   election to the board of commissioners of the commission for certification in geriatric pharmacy dr kevin t bain   health care innovator of the year dr calvin knowlton philadelphia business journal   cxo executive management award michael greenhalgh rph smartceo   e award dr calvin knowlton emerald asset management   remington honor medal dr calvin knowlton american pharmacists association   technology innovator large company dr calvin knowlton smartceo   ernst  young entrepreneur of the year technology dr calvin knowlton philadelphia   growth company of the year carekinesis new jersey technology council   best place to work carekinesis philadelphia business journal   enterprise awards life science startup company carekinesis greater philadelphia alliance for capital and technologies   nj’s best  women in business award dr orsula knowlton nj biz   person of the year award recipient vna of greater philadelphia   heart of hospice award recipient samaritan hospice mt laurel nj   women of distinction award dr orsula knowlton philadelphia business journal   best place to work excellerx philadelphia business journal   deloitte technology fast  company excellerx  in us   walter m aikman entrepreneur of the year dr calvin knowlton greater philadelphia venture group philadelphia   entrepreneur of the year dr calvin knowlton eastern technology council philadelphia   ernst  young entrepreneur of the year technology dr calvin knowlton philadelphia   deloitte  touche technology regional fast  company excellerx philadelphia     apha academy of pharmacy practice and management distinguished achievement award in special pharmaceutical services dr calvin knowlton   us pharmacist of the year dr calvin knowlton american druggist   victor h morgenroth jr award dr calvin knowlton american college of apothecaries   daniel b smith award dr calvin knowlton american pharmaceutical association   presidential citation dr calvin knowlton american college of apothecaries   albert e rossica award dr calvin knowlton new jersey pharmaceutical association   pharmacist of the year dr calvin knowlton society of burlington county pharmacists   we’re hiring systems administrator risk adjustment coder nurse risk adjustment and coding specialist contact information  infotabularasahealthcarecom  strawbridge drivemoorestown nj  tabula rasa healthcare about us  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases about us  how we help improve lives  tabula rasa means “blank slate” in latin and references the roman wax tablet used for notes these tablets were blanked by heating then smoothing the wax to give a tabula rasa contemporary translation includes “fresh start” or “new beginning” the tabula rasa healthcare trhc provides new beginnings for our clients through innovative service models and fresh approaches to healthcare our leaders understand that to maximize patient experiences and outcomes they must help providers to balance efficiency and scalability with safety and individualization of care our culture the trhc way promotes this mentality trhc provides patientspecific datadriven technology and solutions that enable healthcare organizations to optimize medication regimens we improve patient outcomes reduce hospitalizations lower healthcare costs and manage risk we deliver our solutions through a comprehensive suite of technologyenabled products and services for medication risk management and risk adjustment with  billion prescriptions filled in the us in  medication treatment is the most common medical intervention its imprecise use represents the fourth leading cause of death and contributes to an estimated  to  million adverse drug events or ades annually ades result in more than  deaths annually approximately  hospitalizations and one million emergency room visits incidence of ades is highly correlated to the number of medications an individual is taking and to nonadherence and thus is particularly relevant to populations with complex healthcare needs as the us healthcare market continues to evolve from feeforservice to valuebased models of care healthcare organizations require new and emerging technologies to optimize treatment and manage risk on a patientspecific customized basis our solutions are targeted to atrisk organizations that are clinically and financially responsible for the populations they serve our suite of cloudbased software solutions provides prescribers pharmacists and healthcare organizations with sophisticated and innovative tools to better manage the medicationrelated needs of patients trhc offers a prospective clinical approach to medication risk management designed to increase patient safety and promote medication regimen adherence furthermore our medication risk management technology helps healthcare organizations lower costs by reducing ades enhancing quality of care and avoiding preventable hospital admissions we’re hiring systems administrator risk adjustment coder nurse risk adjustment and coding specialist contact information  infotabularasahealthcarecom  strawbridge drivemoorestown nj  bibey post   trending stock news penny stock news market news stock news latest headlines evolent health evh at  forms top granite construction gva’s sentiment is  test granite construction incorporated is a heavy civil contractor and construction materials producer in the united states the company has market cap of  billion the firm operates through three divisions more… parker drilling company pkd reaches  week low bioscrip bios shorts lowered by  hazel jackson the stock of parker drilling company nysepkd hit a new week low and has  target or  below today’s  share price the  months bearish chart indicates high risk for the  million more… genesee valley trust company has cut the priceline group pcln holding by  biocorrx bicx si decreased by  winifred garcia genesee valley trust company decreased the priceline group inc pcln stake by  reported in q sec filing genesee valley trust company sold  shares as the priceline group inc pcln’s stock more… matthew  management has lowered scripps networks interactive sni position by  million rand wealth has increased automatic data processing in adp holding by  million fonar fonr reaches  after  down move mgic investment corp mtg had  analysts last week resources connection inc recn reaches  after  up move acadian timber tseadn had  bullish analysts green square capital has lifted its att com t position bbt capital management has upped amc networks call amcx stake by  american capital management cut its verint systems vrnt holding deutsche lufthansa ag etrlha covered by  bullish analysts last week lowe brockenbrough  company has cut by  million its cvs health com cvs position  analysts covering compass diversified holdings codi davidson d a  company lifted amgen amgn stake last week orion group holdings orn analysts davidson investment advisors trimmed its potlatch holdings new pch position dimensional fund advisors lp has lifted by  million its netflix nflx stake cypress capital group upped by  million its microsoft msft stake  analysts are bullish topbuild bld last week df dent  co has increased tyler technologies tyl position orasure technologies osur sentiment is  santa barbara asset management boosted monsanto co mon stake by  million belmond limited bel shorts raised by  united capital financial advisers lowered its mainsource financial group msfg holding shorts at beiersdorf a g bdrff raised by  chilton investment co has trimmed hunt j b trans svcs jbht holding by  commscope holding company comm has  sentiment chilton investment co has lifted its pepsico pep position renault sa eur rnsdf had  bulls vertex one asset management upped golar lng partners lp gmlp holding babcock  wilcox enterprises bw shorts up by  metropolitan life insurance company upped oasis petroleum oas stake hysteryale materials handling has  sentiment horizon kinetics boosted by  million its royce micro rmt position turtle creek asset management has boosted pra group praa position contour asset management cut computer sciences csc position abraxas petroleum axas has  sentiment schneider national sndr reaches  after  up move haverford trust company has lifted its pfizer pfe position free newsletter enter your email address below to get the latest news and analysts ratings for your stocks with our free daily email newsletter recent posts evolent health evh at  forms top granite construction gva’s sentiment is  parker drilling company pkd reaches  week low bioscrip bios shorts lowered by  genesee valley trust company has cut the priceline group pcln holding by  biocorrx bicx si decreased by  matthew  management has lowered scripps networks interactive sni position by  million rand wealth has increased automatic data processing in adp holding by  million fonar fonr reaches  after  down move mgic investment corp mtg had  analysts last week resources connection inc recn reaches  after  up move acadian timber tseadn had  bullish analysts green square capital has lifted its att com t position bbt capital management has upped amc networks call amcx stake by  american capital management cut its verint systems vrnt holding deutsche lufthansa ag etrlha covered by  bullish analysts last week lowe brockenbrough  company has cut by  million its cvs health com cvs position  analysts covering compass diversified holdings codi davidson d a  company lifted amgen amgn stake last week orion group holdings orn analysts  copyright  bibey post inc  bibeypostcom       about  our team  contact tabula rasa healthcare inc  trhc  stock price today  zacks trhc is up  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more tabula rasa healthcare inc trhc delayed data from nsdq  usd     updated jul    pm et add to portfolio zacks rank hold          style scores d value  d growth  c momentum  d vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank bottom  out of  industry medical info systems view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date amc prior year eps  exp eps growth yr forward pe  peg ratio  medical » medical info systems bmo  before market open amc  after market close zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research report for trhc all zacks’ analyst reports news for trhc zacks news for trhc other news for trhc can tabula rasa trhc run higher on strong earnings estimate revisions am est zacks trhc what are zacks experts saying now zacks private portfolio services more zacks news for trhc premarket analyst action  healthcare am est seeking alpha breakout watch thinly traded health care ipo enters buy zone am est investors business daily tabula rasa healthcare to provide care transition medication management for tandigm health pm est gurufocus tabula rasa healthcare to participate in the ¿¿¿¿¿¿¿¿¿ ubs global healthcare conference am est gurufocus tabula rasa healthcare and landmark to improve patient outcomes in california and new york ¿¿¿¿ am est gurufocus more other news for trhc premium research for trhc zacks rank hold  zacks industry rank bottom  out of  zacks sector rank bottom   out of  style scores d value  d growth  c momentum  d vgm earnings esp  research report for trhc snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank tabula rasa healthcare inc trhc athenahealth inc athn cerner corporation cern computer programs and systems inc cpsi streamline health solutions inc strm biotricity inc btcy digirad corporation drad see all medical info systems peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary tabula rasa healthcare inc is a provider of patientspecific datadriven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes reduce hospitalizations lower healthcare costs and manage risk the companys cloudbased software applications including eirenerx and medwise advisor which provide solutions to payers providers and other healthcare organizations tabula rasa healthcare inc is based in nj united states tabula rasa healthcare legal  tabula rasa healthcare  email us careers contact us open menuabout us our story our brands awards  recognition careers leadership board of directors our technology our mrm matrix our software software development our solutions our services our outcomes for health plans investors news press releases legal the information contained in this website is for general information purposes only the information is provided by tabula rasa healthcare and while we endeavor to keep the information up to date and correct we make no representations or warranties of any kind express or implied about the completeness accuracy reliability suitability or availability with respect to the website or the information products services or related graphics contained on the website for any purpose any reliance you place on such information is therefore strictly at your own risk in no event will we be liable for any loss or damage including without limitation indirect or consequential loss or damage or any loss or damage whatsoever arising from loss of data or profits arising out of or in connection with the use of this website through this website you are able to link to other websites which are not under the control of tabula rasa healthcare we have no control over the nature content and availability of those sites the inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them every effort is made to keep the website up and running smoothly however tabula rasa healthcare takes no responsibility for and will not be liable for the website being temporarily unavailable due to technical issues beyond our control for additional information please contact us at infotabularasahealthcarecom we’re hiring systems administrator risk adjustment coder nurse risk adjustment and coding specialist contact information  infotabularasahealthcarecom  strawbridge drivemoorestown nj